{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"005-999-706-282-870","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"005-999-706-282-870","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11646,"type":"PATENT","title":"UT M. D. Anderson Cancer Center - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4091,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8312,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:anderson cancer texas
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4097
Search Applicants and Owners separately:anderson cancer texas
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4097
administering to a patient at risk for recurrence of HPV-associated pre-cancerous or cancerous growth an effective amount of at least one E6 or E7 HPV peptide, wherein a cell-mediated immune response to at least one E6 or E7 peptide is induced in the patient and the cell-mediated immune response to such at least one peptide is indicative of a reduced risk of recurrence."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the patient is administered an effective amount of an E6 HPV peptide."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the E6 peptide is K9L (SEQ ID NO:1), E10I (SEQ ID NO:2), C10R (SEQ ID NO:3), Q15L (SEQ ID NO:4), V10C (SEQ ID NO:5), P9L (SEQ ID NO:6), P10I (SEQ ID NO:7), Q20P (SEQ ID NO:8), R16R (SEQ ID NO:9), or G10S (SEQ ID NO:10)."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the patient is administered a combination of E6 HPV peptides selected from the group consisting of K9L (SEQ ID NO: 1), E10I (SEQ ID NO:2), C10R (SEQ ID NO:3), Q15L (SEQ ID NO:4), and V10C (SEQ ID NO:5)."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the patient is administered an effective amount of an E7 HPV peptide."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, wherein the E7 HPV peptide is T10Q (SEQ ID NO:11), M9T (SEQ ID NO:12), D9L (SEQ ID NO:13), Q19D (SEQ ID NO:14), R9F (SEQ ID NO:15 ), R9V (SEQ ID NO:16), L9V (SEQ ID NO:17), G10C (SEQ ID NO:18), or D20C (SEQ ID NO:19)."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, wherein the patient is administered a combination of E7 HPV peptides selected from the group consisting of T10Q (SEQ ID NO:11), M9T (SEQ ID NO:12), D9L (SEQ ID NO:13), Q19D (SEQ ID NO:14), R9F (SEQ ID NO:15), R9V (SEQ ID NO:16), L9V (SEQ ID NO:17), G10C (SEQ ID NO:18), and D20C (SEQ ID NO:19)."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the patient is administered at least one E6 HPV peptide and at least one E7 HPV peptide."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the patient has a history of a pre-cancerous growth."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the pre-cancerous growth is cervical intraepithelial neoplasia (CIN)."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the patient has a history of a cancerous growth."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 11, wherein the patient has a history of cervical cancer."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the patient has undergone ablative treatment of a pre-cancerous or cancerous growth in the genitourinary tract."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the ablative treatment is selected from the group consisting of chemotherapy, radiotherapy, hormonal therapy, gene therapy, surgery, gene therapy, and immunotherapy."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the at least one E6 or E7 HPV peptides are comprised in a pharmaceutical composition."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the pharmaceutical composition further comprises an adjuvant."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the pharmaceutical composition further comprises a lipid."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein the lipid is a phosphatidylglycerol, a phosphatidylcholine, a phosphatidylserine, a phosphatidylethanolamine, a sphingolipid, a cerebroside, or a ganglioside."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 18, wherein the lipid is a phosphatidylglycerol."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 19, wherein the phosphatidylglycerol is diacylphosphatidyglycerol."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein identifying a patient at risk for recurrence of HPV-associated pre-cancerous or cancerous growth comprises performing a Pap Smear test."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein identifying a patient at risk for recurrence of HPV-associated pre-cancerous or cancerous growth comprises performing colposcopy on the subject."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein administering to the patient an effective amount of at least one E6 or E7 HPV peptide comprises administering to the patient an expression construct comprising a nucleic acid sequence coding for at least one E6 or E7 HPV peptide wherein the nucleic acid sequence is under the transcriptional control of a promoter."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 23, wherein the expression construct is comprised in a viral vector."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 24, wherein the viral vector is a retroviral vector, an adenoviral vector, an adeno-associated viral vector, a vaccinia virus vector, or a herpes virus vector."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 23, wherein the expression construct is comprised in a liposome."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the at least one E6 or E7 HPV peptide is administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intravaginally, rectally, topically, intratumorally, intramuscularly, subcutaneously, mucosally, orally, or topically."],"number":27,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}